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Background: Understanding their experiences of diagnosis is integral to improving the quality of care for women living with
advanced/metastatic breast cancer.
Methods: A survey, initiated in March 2011, was conducted in two stages. First, the views of 47 breast cancer-related patient
groups in eight European countries were sought on standards of breast cancer care and unmet needs of patients. Findings were
used to develop a patient-centric survey to capture personal experiences of advanced breast cancer to determine insights into the
‘trade-off’ between extending overall survival and side effects associated with its treatment. The second online survey was open to
women with locally advanced or metastatic breast cancer, or their carers, and responders were recruited through local patient
groups. Data were collected via anonymous local language questionnaires.
Results: The online stage II survey received a total of 230 responses from 17 European countries: 94% of respondents had locally
advanced or metastatic breast cancer and 6% were adult carers. Although the overall experience of care was generally good/
excellent (77%), gaps were still perceived in terms of treatment choice and information provision. Treatment choice for patients
was felt to be lacking by 32% of responders. In addition, 68% of those who responded would have liked more information about
future medical treatments and research, with 57% wishing to receive this information from their oncologist. Two-thirds (66%)
of women with advanced breast cancer, or their carers, believed life-extending treatment to be important so that they can spend
more time with family and friends, and 67% said that the treatment was worthwhile, despite potential associated side effects.
Conclusion: These findings show a continuing need to provide women with advanced breast cancer with better information and
emphasise the importance that these patients often place on prolonging survival.
Breast cancer is the most common cancer in women in most
countries and the leading cause of cancer-related death in women
worldwide. In 2008, there were an estimated 421 000 new cases of
breast cancer diagnosed in Europe (Ferlay et al, 2010) and
1.4million worldwide (Ferlay et al, 2008). The incidence of breast
cancer worldwide is predicted to rise to 2.3 million by 2030,
although mortality rates in Western countries are falling because of
earlier detection and effective adjuvant treatment (Ferlay et al,
2008). Nevertheless, for the 4–6% of women with metastatic
disease at diagnosis (Cardoso et al, 2011), and the approximately
30% who present with early breast cancer but later develop
metastatic breast cancer (Shaughnessy, 2005), treatment effectively
remains palliative. Although the median survival from diagnosis of
metastatic disease is 2–3 years, in indolent disease, it may be as
long as 10–15 years (Johnston and Swanton, 2006). Hence, as the
prevalence of advanced breast cancer increases, and overall survival
is slowly extended, the needs of women living with metastatic
disease continue to pose a major challenge for healthcare
professionals.
The specific aims of treatment for patients with metastatic
and locally advanced breast cancer vary depending on their
presentation, symptoms and circumstances, but most patients and
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clinicians have a common goal of alleviating symptoms, main-
taining quality of life and prolonging survival. Treatment options
may include not only approved and generally available local and
systemic therapies but also the possibility of participation in
clinical trials. Factors that influence clinicians in treatment
strategies include the molecular phenotype of the cancer, the site
and extent of metastatic disease, the fitness of the patient, their
prior therapy and any potential complications related to that
treatment, as well as the patient’s own preferences (Chung and
Carlson, 2003). Providing adequate information for patients
to be actively involved in decision making is an important role
for healthcare professionals.
How patients use the information offered to them will
undoubtedly vary, but we believe that many women living with
advanced breast cancer share similar needs and opinions that are
specific to their disease. The literature reports that information
needs are high in patients with metastatic breast cancer (Mayer,
2010) and that those who have their needs me express much less
anxiety and lower likelihood of depression (Mayer and Grober,
2006). Despite this evidence, patients living with advanced breast
cancer continue to encounter challenges in accessing the required
information and support. Indeed 90% of patients diagnosed with
advanced breast cancer questioned in one study reported that they
received less attention and less information than at the time of
their initial diagnosis (Cella et al, 1990) and other studies have
reported that the majority of patients found the diagnosis of
recurrence to be more distressing than the original diagnosis (Cella
et al, 1990; Mahon et al, 1990). Learning what patients want from
their healthcare providers is an important step in addressing their
concerns and meeting their psychosocial needs.
Several studies have looked at how patients with cancer
(although not specifically breast cancer) view the relative
importance of improved survival as opposed to greater treatment
toxicity. Some have suggested that patients would accept
considerable toxicity for very modest improvements in survival
(Wong et al, 2012), whereas others have suggested that an
improvement in survival alone is not sufficient in the trade-off
against treatment-related toxicities (Bridges et al, 2012). There is,
however, relatively little information specifically in the context of
metastatic breast cancer. Interestingly though, a study in women
with early breast cancer indicated that 76% would choose
alleviation of symptoms rather than prolonged survival in a
hypothetical scenario of metastatic disease (McQuellon et al, 1995).
To date, there is very little understanding of whether women living
with metastatic breast cancer are willing to tolerate treatment-
related toxicities in order to extend their life, or what information
and support they would like to help them to decide. Of course, the
distinction between progression-free and overall survival may be a
difficult concept to grasp when contemplating further aggressive
treatments (or on deciding to have better tolerated therapies or no
active treatment), and explanation and clarification are central to
helping patients make such decisions.
In order to provide the best care for patients living with
advanced breast cancer, we need to know more about their
experiences of diagnosis, treatment and care. For the information
to be useful, transferable and as widely applicable as possible, we
undertook a two-part, pan-European survey of patients (or their
carers) living with metastatic/advanced breast cancer. This is the
first European-wide study to be conducted specifically aimed at
gaining a better understanding of the needs of these patients.
As the prevalence of advanced breast cancer increases because of
increasing incidence and reducing mortality, this information
will become increasingly more relevant in both developed and
developing countries. The information obtained from this pan-
European study should empower patients, their carers, clinicians
and managers to improve lines of communication and restructure
services to address the needs of this patient group.
MATERIALS AND METHODS
The survey, initiated in March 2011, was conducted using a
two-stage methodology developed in conjunction with academic
and patient organisations. This methodology has been validated as
an effective means of measuring patients’ perspectives in healthcare
systems (Wyke et al, 2008). The two-stage design was intended to
overcome the limitations inherent in existing methodology; namely
that questionnaires and surveys are typically constructed without
first exploring patients’ own opinions on the subject in question.
In 2011, the first stage of the ‘Being There‘ survey was
conducted among 47 patient groups based in eight European
countries, all of which had links with patients living with locally
advanced or metastatic breast cancer. Their views on standards
of care and unmet needs of patients with metastatic and locally
advanced breast cancer were sought through 14 open-ended
questions allowing the groups to respond as comprehensively as
they wished. Responses were collated from Belgium, France,
Germany, Italy, Sweden, Switzerland and the United Kingdom.
The results were used to design the survey for stage II by
formulating the patient group statements into a multiple-choice
questionnaire, from which respondents were asked to specify their
priorities from a list of options.
The second stage was planned to identify the important issues
faced by women with locally advanced and metastatic breast cancer
in an online survey (Supplementary Appendix 1) open to women
aged 20 years or older (no upper age limit) with locally advanced or
metastatic breast cancer, or their carers, at any stage in their
treatment. Responders were recruited through local patient groups,
and data were collected via anonymous local language question-
naires. The translations were performed in accordance with current
good practice in translation of international survey questionnaires.
The English master version was subject to parallel translation into
the language of choice by independent translators familiar with
survey research. ‘Back translation’ was conducted to check validity
of the terminology and the translated version was pretested in the
participating country. The questionnaire explored topics including
patients’ personal experiences of diagnosis and treatment, the
attitudes of health professionals within their cancer services, the
information provided and made available and patients’ views on
improving the future care offered. The study also sought to gain
insight into the ‘trade-off’ between extending overall survival and
treatment-related side effects. PatientView, an independent
research-and-publishing organisation, who were involved in the
design of the questionnaire, performed the analyses.
RESULTS
A wide variety of patient support groups were contacted, all of
whom had direct contact with patients with advanced breast
cancer. Fifty-eight percent of these groups cited breast cancer as
their organisation’s main ‘specialisation’, others stated palliative
care, bereavement, carers and women’s health as their main
provision of support (Supplementary Appendix 2). Groups from
Belgium(3), France(14), Germany(13), Italy(22), Spain(9),
Sweden(23), Switzerland(3) and the United Kingdom(18) took
part. The responses given were varied but often repeated by other
groups from other countries. The most frequently repeated answers
from stage I are shown graphically in a series of charts in
Supplementary Appendix 2.
In Stage II of the study, a total of 230 responses were received
from 17 European countries; 216 responders (94%) had locally
advanced or metastatic breast cancer and 14 (6%) were adult carers
(Table 1). The details of the online survey were distributed by
patient support groups and hence the number of people deciding
BRITISH JOURNAL OF CANCER A pan-European survey of patients with MBC
1544 www.bjcancer.com |DOI:10.1038/bjc.2013.492
not to take the survey is unknown. Most responders (77%) rated
their care as good to excellent, but clear gaps were evident in both
the treatment choice and information provision for these patients.
Treatment choice. A third (32%) of patients/carers perceived
treatment choice within their country’s healthcare system to be
lacking. The majority (59%) felt they had choice in the treatment
decisions, and only 21% had been informed of treatments available
through clinical trials. Nevertheless, half (56%) reported that they
were not advised about treatment options available outside of their
hospital.
Information provision. Patients/carers need more information
on treatment-related issues (Figure 1). Two-thirds (68%) of
responders wanted more information about future medical
treatments and research; the majority of patients/carers felt that
this information should come from their oncologist. Half (53%) of
patients/carers wanted to receive information on treatments
currently in clinical trials and the same proportion (55%) wanted
more information on the balance between the benefits of treatment
and the risks.
Quality of care. Important areas were identified where healthcare
professionals could improve the quality-of-care provision to
women with locally advanced or metastatic breast cancer
(Figure 2). About half of patients/carers felt their care would be
enhanced if healthcare professionals listened more to patients
(51%); ensured continuity of care with the same doctors, nurses
and specialists (55%); reduced waiting times for access to treatment
(52%); and ensured counselling was available if required (55%).
Life-extending treatments. Survival was the priority for the
majority of women with locally advanced or metastatic breast
cancer, patients being willing to ‘trade-off’ drug side effects in
order to prolong their life (Figure 3). Two-thirds (67%) of patients/
carers believed life-extending treatment to be important in order to
extend time spent with family and friends, and two-thirds (64%)
judged treatment worthwhile if it prolonged survival, irrespective
of potential side effects. Only 4% of patients indicated that they
would rather live out the time they have peacefully, without
treatment.
Additional free text comments. Following the multiple choice
questions, 15 patients took the opportunity to make further
comments. These comments varied from expressing a desire to
meet other women in the same situation as themselves to gratitude
that healthcare professionals were interested in their opinion, to
frustration with lack of support services, out of hours assistance
and delays in diagnosis and commencing therapy.
DISCUSSION
Despite sustained advances in the treatment of locally advanced
and metastatic breast cancer over the last few decades, it remains
essentially incurable. The ‘Being There’ survey highlights
significant unmet needs among European women and their carers
living with metastatic breast cancer. In particular, they want more
information regarding their treatment options, including those
available in clinical trials. One of the aspects of care that could be
improved was also identified as better communication. Never-
theless, for most women, survival was their priority, with them
expressing a willingness to ‘trade-off’ the side effects of treatment
against prolonging their lives.
This survey serves as a valuable reminder that, for most
European women with locally advanced or metastatic breast
cancer, survival is their main priority, with most willing to suffer
treatment-related toxicities if the treatment will prolong their
life. Importantly, patients’ views regarding chemotherapy in the
palliative setting for all cancers are different from those of a well
person or their physicians (Matsuyama et al, 2006; Slevin et al,
1990; Degner and Sloan, 1992), with patients willing to undergo
treatments that have relatively small benefits but significant
toxicity. Indeed, in one study, 15% of women who had already
undergone treatment for stage I–IIIA breast cancer would choose a
high-dose experimental chemotherapy for as little as 1 month of
added life expectancy (McQuellon et al, 1995). It is important,
however, that patients are sufficiently informed so they can
appreciate and understand that a toxic treatment that improves
progression-free survival by 1 month does not necessarily equate to
an additional month of life.
Over recent years, there has been considerable emphasis on
improving communication with patients with cancer. It is of note
Table 1. Demographics of patient/carer responders to stage II
Age (years) %
Under 20 0
20–29 2
30–39 7
40–49 32
50–59 33
60–69 23
70–79 1
80 or older 2
Breast cancer patient 94
Carer 6 (all female)
Country of residence
Cyprus 2
Czech Republic 2
Denmark 4
Greece 2
Hungary 16
Iceland 1
Ireland 3
Lithuania 1
Poland 1
Romania 1
Sweden 7
United Kingdom 47
Other 7
Unanswered 6
Treatment information needs of patients
living with metastatic breast cancer 
Choice of specialist
Complimentary therapies
Non-medical treatment, e.g., counselling
Advice re-monetary support for treatment
Relevance to personal situation
% Patient groups 
Risks vs benefits of treatment
Treatments in clinical trials
Future treatments & research
0 20 40 60 80
Figure 1. Treatment information needs in metastatic breast cancer.
What further related information is required.
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that the women and carers in this survey perceived there to be a
lack of information, suggesting current practice may not translate
into an optimal patient experience. Furthermore, the survey
participants expressed a desire to be more involved in decision
making. Treatment preferences for patients with metastatic breast
cancer may differ between the woman and her physician due to
differing value systems and personal judgements on risk–benefit
ratios. Indeed, broad differences exist between different oncologists
as to their preferred treatment option (Koedoot et al, 2002),
emphasising the importance of the individual patient’s preferences
and involvement in the decision-making process. Interestingly,
despite the increased role of nurses and others in supporting
patients with breast cancer, the preference that women receive
information from their oncologist noted in the past persists.
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0
Treatment means I can enjoy additional 
time with family/friends
Life-extending treatment is worth the side 
effects 
I would rather live out the time I have 
peacefully than undergo treatment that 
has moderate side-effects
I would rather live out the time I have 
peacefully than undergo treatment that 
has severe side-effects
None of the options
I don't know
% Patient response
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Figure 3. Treatment priorities for women with locally advanced and MBC.
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Better information on clinical trials and access to trials was
highlighted as a specific priority. Historically, only 5% of women
with breast cancer are enroled into clinical trials (Cohen et al,
2012), with lack of knowledge or adequate information being one
of the foremost obstacles to participation (Simon et al, 2004). In
the United Kingdom, which has a well-developed National Cancer
Research Network, over 2011 to 2012, only 10% of incidence cases
of all breast cancer were enroled into a randomised controlled trial.
This survey suggests that collectively we are failing to give our
patients the access to clinical trials that they seek. Guidelines from
the European Society for Medical Oncology for the management of
metastatic breast cancer advise that participation in clinical trials
should be offered to all eligible patients, wherever available
(Cardoso et al, 2011).
Although many patient support and health groups have
developed excellent on-line resources to help patients’ access
information on clinical trials, several issues are evident. First,
because of the rapidity of new trials becoming available, this
information is very difficult to keep up to date in any other media
than the internet. Hence, patients with little access to the internet
are equally likely to be excluded from this repository of
information. Second, the amount of information on clinical trials
for all cancers is somewhat overwhelming, and accessing appro-
priate trials may be difficult without a patient knowing her disease
in detail. Although the ESMO website has excellent links to non-
tumour-site-specific websites, most are in English or only a few
European languages, and navigating to clinical trials specifically for
metastatic breast cancer is not easy. The EuropaDonna.org
provides an excellent introduction to clinical trials, although none
of the broader support websites have identifiable links for women
with advanced breast cancer. Perhaps, both online and paper-based
resources could be made available, which are specifically aimed at
patients with advanced breast cancer, clearly signposted. The
United Kingdom has recently recognised the isolation felt by this
cohort of patients, and the Secondary Breast Cancer Awareness
Day is now a part of the Breast Cancer Awareness month dedicated
to publicising the issues affecting people with secondary breast
cancer. We would encourage other countries to adopt such days.
In the current era of personalised medicine, we suggest a more
personalised route to information and perhaps the design of
specific apps, which can be regularly updated, and even provided in
the waiting rooms of clinics, in which patients click on a series of
options to guide them to appropriate trials may be an appropriate
solution to balancing busy clinics and introducing trials to patients.
However, none of this removes the need for discussion of
management and care with the patient and carer, and this should
include face-to-face discussion of appropriate trials, if the patient
and the physician think it to be appropriate.
A worrying one-third of patients and carers in this survey
perceived the options available within their countries’ healthcare
system to be lacking. Moreover, greater than half of the
participants were not advised about treatment options available
outside of their treatment centre. The wave of ‘re-centralisation’ of
healthcare services in many European countries (Saltman, 2008)
represents an opportunity for patients to be appraised of a wider
range of treatment options in specialist centres, including
participation in clinical trials. Despite the apparent shortcomings
identified in this study, it is re-assuring that survey participants
generally rated their current cancer care as good or excellent.
Inevitably, there are limitations to this study. Although the two-
pronged design goes some way to tailoring the survey questions to
its respondents, the online methodology restricts participation to
those with internet access, and hence it is likely to under-represent
minorities, older and less well-educated patients, as well as those
from lower socioeconomic groups. However, the dissemination of
the questionnaire details through the patient support groups was
one attempt to open this survey to patients/carers not actively
seeking information online, and the multilanguage survey hoped to
eradicate the bias for English speakers. Inevitably, the very nature
of such a survey is likely to be biased towards those patients
actively seeking information, including details of clinical trials, and
hence our survey results may over estimate the number of women
seeking such information. However, similar results have been
identified in the ‘Silent Voices’ survey (Mayer and Grober, 2006)
conducted in the USA (also an online survey) and re-iterate the
previously reported isolation felt by women living with advanced
breast cancer. The number of responses is also modest, but,
being sourced from 17 countries, they do provide a pan-European
perspective.
In summary, these findings provide an insight into the unmet
needs of women living with locally advanced and metastatic breast
cancer in Europe and should be used to improve their services,
with an emphasis on improving the provision of information and
enhancing patient involvement in decision making.
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